Overview

Combination Drug Therapy for Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma

Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
Proposed treatment of subjects with newly diagnosed glioblastoma with novel personalized drug regimens identified to be effective in vitro using cancer stem cells derived from their individual tumors, alongside standard of care radiation and TMZ.
Phase:
Early Phase 1
Details
Lead Sponsor:
Swedish Medical Center